Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram in High-Risk Youth With Depression or Anxiety
NCT02553161Completed
- Sponsor
- University of Cincinnati
- Start
- Dec 2015
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of escitalopram in major depressive disorder (MDD) and anxiety disorder (3 arms), sponsored by University of Cincinnati. Primary endpoint: Baseline-endpoint change in prefrontal-amygdala functional connectivity by Scan at 16 weeks. Started Dec 2015; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT02553161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553161.